NASDAQ:BEAT - BioTelemetry Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $49.80 +0.60 (+1.22 %) (As of 07/17/2018 03:36 PM ET)Previous Close$49.35Today's Range$49.25 - $50.4052-Week Range$23.30 - $49.45Volume9,463 shsAverage Volume271,267 shsMarket Capitalization$1.62 billionP/E Ratio51.49Dividend YieldN/ABeta1.41 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania. Receive BEAT News and Ratings via Email Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Specialty outpatient clinics, not elsewhere classified Sub-IndustryN/A SectorMedical SymbolNASDAQ:BEAT CUSIPN/A Webwww.gobio.com Phone610-729-7000 Debt Debt-to-Equity Ratio0.77 Current Ratio1.96 Quick Ratio1.83 Price-To-Earnings Trailing P/E Ratio51.49 Forward P/E Ratio37.44 P/E Growth3.7 Sales & Book Value Annual Sales$286.78 million Price / Sales5.69 Cash Flow$1.8921 per share Price / Cash26.32 Book Value$7.70 per share Price / Book6.47 Profitability EPS (Most Recent Fiscal Year)$0.97 Net Income$-15,950,000.00 Net Margins-3.13% Return on Equity16.63% Return on Assets8.62% Miscellaneous Employees1,600 Outstanding Shares32,790,000Market Cap$1,615.10 BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions What is BioTelemetry's stock symbol? BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT." How were BioTelemetry's earnings last quarter? BioTelemetry Inc (NASDAQ:BEAT) released its quarterly earnings data on Wednesday, April, 25th. The medical research company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.16. The medical research company had revenue of $94.50 million for the quarter, compared to analyst estimates of $91.55 million. BioTelemetry had a negative net margin of 3.13% and a positive return on equity of 16.63%. The business's quarterly revenue was up 69.1% compared to the same quarter last year. During the same period last year, the firm earned $0.16 earnings per share. View BioTelemetry's Earnings History. What price target have analysts set for BEAT? 6 Wall Street analysts have issued 1 year price targets for BioTelemetry's stock. Their forecasts range from $37.00 to $54.00. On average, they expect BioTelemetry's share price to reach $44.40 in the next year. This suggests that the stock has a possible downside of 11.2%. View Analyst Ratings for BioTelemetry. What is the consensus analysts' recommendation for BioTelemetry? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of BioTelemetry's key competitors? Some companies that are related to BioTelemetry include SWEDISH ORPHAN/S (SWTUY), PRA Health Sciences (PRAH), Canopy Growth (WEED), Canopy Growth (CGC), ICU Medical (ICUI), Hill-Rom (HRC), Stada Arzneimittel (STDAF), Catalent (CTLT), BIO-TECHNE (TECH), Ionis Pharmaceuticals (IONS), Charles River Laboratories Intl. (CRL), Integra Lifesciences (IART), Dr.Reddy's Laboratories (RDY), DiaSorin (DSRLF) and United Therapeutics (UTHR). Who are BioTelemetry's key executives? BioTelemetry's management team includes the folowing people: Mr. Joseph H. Capper, CEO, Pres & Director (Age 54)Ms. Heather C. Getz, Exec. VP & CFO (Age 43)Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 49)Mr. Fred Broadway III, Pres of BioTel Heart (Age 48)Dr. Peter R. Kowey M.D., FACC, FACP, FACCP, FCP, Medical Director and Chairman of Medical Advisory Board Has BioTelemetry been receiving favorable news coverage? Media headlines about BEAT stock have been trending somewhat positive on Tuesday, according to Accern. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioTelemetry earned a news impact score of 0.13 on Accern's scale. They also assigned media coverage about the medical research company an impact score of 45.04 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Who are BioTelemetry's major shareholders? BioTelemetry's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.48%), Columbia Partners L L C Investment Management (0.12%), Mesirow Financial Investment Management Inc. (0.04%), Fox Run Management L.L.C. (0.03%), Mckinley Capital Management LLC Delaware (0.01%) and Fortaleza Asset Management Inc. (0.01%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry. Which major investors are selling BioTelemetry stock? BEAT stock was sold by a variety of institutional investors in the last quarter, including Columbia Partners L L C Investment Management, Scout Investments Inc., Mesirow Financial Investment Management Inc., Mckinley Capital Management LLC Delaware and Fortaleza Asset Management Inc.. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Insider Buying and Selling for BioTelemetry. Which major investors are buying BioTelemetry stock? BEAT stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. View Insider Buying and Selling for BioTelemetry. How do I buy shares of BioTelemetry? Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioTelemetry's stock price today? One share of BEAT stock can currently be purchased for approximately $50.00. How big of a company is BioTelemetry? BioTelemetry has a market capitalization of $1.62 billion and generates $286.78 million in revenue each year. The medical research company earns $-15,950,000.00 in net income (profit) each year or $0.97 on an earnings per share basis. BioTelemetry employs 1,600 workers across the globe. How can I contact BioTelemetry? BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected] MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 235 (Vote Outperform)Underperform Votes: 203 (Vote Underperform)Total Votes: 438MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: What is a closed-end mutual fund (CEF)?